Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology.
It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells.
Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.
As of August 23, 2023, Apexigen, Inc. operates as a subsidiary of Pyxis Oncology, Inc..
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | 0.00 Increased by +100.00% | -0.19 Increased by +100.00% |
| Aug 10, 23 | -0.24 Increased by +47.83% | -0.19 Decreased by -26.32% |
| May 16, 23 | -0.25 Decreased by -2.40 K% | -0.19 Decreased by -31.58% |
| Feb 22, 23 | -0.33 Decreased by -2.18 K% | -0.36 Increased by +8.33% |
| Nov 15, 22 | -0.41 Decreased by -4.20 K% | -0.28 Decreased by -46.43% |
| Aug 18, 22 | -0.46 Decreased by -1.05 K% | - |
| Apr 7, 22 | -0.01 Increased by +50.00% | - |
| Dec 31, 21 | -0.01 Decreased by N/A% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -6.05 M Increased by +99.61% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.89 M Decreased by -2.00 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -6.21 M Increased by +23.24% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -8.19 M Decreased by -10.96 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -1.56 B Decreased by -453.53% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -280.95 K Increased by +95.67% | Decreased by N/A% - |
| Dec 31, 21 | 0.00 Decreased by N/A% | -8.09 M Decreased by -733.63 K% | Decreased by N/A% - |
| Sep 30, 21 | 0.00 - | 75.37 K - | Increased by +N/A% - |